Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
about
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Role of Bruton's tyrosine kinase in B cells and malignancies.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.Chronic lymphocytic leukemia at ASH 2017.Critical molecular pathways in CLL therapy.NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia
P2860
Q38654101-A6EBAA90-1847-4618-906C-A6430ECECFE0Q47780043-F3DA1962-7267-44F0-A46B-D2152ED7E7C7Q48256659-B256FD52-887E-40FB-B253-530457F52F09Q48307279-3E880923-C022-4A97-8494-5BBD454CE0A1Q49582344-6059E6FF-0C11-4B25-B674-A35F14196BE8Q49888075-AF0AC1C6-3200-45B0-960A-37A60C47C403Q50110556-9D769E38-3833-4930-BBD2-5D68AE1C8479Q52576558-6F65780C-FA15-4551-959F-5BCD34E03DA6Q52658499-0E027BBF-47C6-44D0-B9E4-1C05155F9FB9Q55422218-142D8879-1826-45F4-AA5F-4D52B6A26F81Q55447785-98708378-A98F-4AD9-898C-D4009F7C7707Q55668973-770D9FE3-BC7A-4A3E-B977-EB7367D36D91Q57821050-106C1C5F-9270-41FA-88DB-59E7727F3385
P2860
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Extended follow-up and impact ...... th previously treated CLL/SLL.
@en
Extended follow-up and impact ...... th previously treated CLL/SLL.
@nl
type
label
Extended follow-up and impact ...... th previously treated CLL/SLL.
@en
Extended follow-up and impact ...... th previously treated CLL/SLL.
@nl
prefLabel
Extended follow-up and impact ...... th previously treated CLL/SLL.
@en
Extended follow-up and impact ...... th previously treated CLL/SLL.
@nl
P2093
P2860
P356
P1433
P1476
Extended follow-up and impact ...... th previously treated CLL/SLL.
@en
P2093
F Caligaris-Cappio
F Cymbalista
J A Burger
J C Barrientos
P2860
P2888
P356
10.1038/LEU.2017.175
P5530
P577
2017-06-08T00:00:00Z
P6179
1085930429